Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: An ancillary study of the Novartis CICL670A0107 trial

Haematologica

Volumn 93, Issue 6, 2008, Pages 817-825

  Walter, Patrick B ^a   Macklin, Eric A ^b,c   Porter, John ^d   Evans, Patricia ^d   Kwiatkowski, Janet L ^e   Neufeld, Ellis J ^f   Coates, Thomas ^g   Giardina, Patricia J ^h   Vichinsky, Elliott ^a   Olivieri, Nancy ⁱ   Alberti, Daniele ^j   Holland, Jaymes ^j   Harmatz, Paul ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

^h NEW YORK PRESBYTERIAN HOSPITAL   (United States)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

C reactive protein; hsCRP; Inflammation; Iron overload; Lipid peroxidation; Malondialdehyde; Oxidative stress; Thalassemia; Vitamin C; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; CYTOKINE; DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON; MALONALDEHYDE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; INFLAMMATION; IRON STORAGE; MALE; MULTICENTER STUDY; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; ASCORBIC ACID; BENZOIC ACIDS; BETA-THALASSEMIA; C-REACTIVE PROTEIN; CHILD; DEFEROXAMINE; FEMALE; HUMANS; IRON CHELATING AGENTS; LIPID PEROXIDATION; MALE; OXIDANTS; OXIDATIVE STRESS; TRIAZOLES; VITAMIN E;

EID: 44949113103     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11755     Document Type: Article

References (62)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
2. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, et al. High incidence of cardiomyopathy in b-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990;84: 113-7.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
4. Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005;80: 70-4.
5. Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol 2005;42 [Suppl 1]:S19-21.
6. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 1999;273:212-20.
7. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996;88:705-13.
8. Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 2006;30:183-200.
9. Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, Hair T, et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. Ann Y Acad Sci 2005;1054:155-68.
10. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-80.
11. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood 2006;107:3455-62.
12. Glickstein H, Ben El R, Link G, Breuer W, Konijn AM, Hershko C, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006;108:3195-203.
13. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005;106:3242-50.
14. Cighetti G, Duca L, Bortone L, Sala S, Nava I, Fiorelli G, et al. Oxidative status and malondialdehyde in b-thalassaemia patients. Eur J Clin Invest 2002;32[Suppl 1]:55-60.
15. Walter PB, Fung E, Killilea DW, Jiang Q, Hudes M, Madden J, et al. Oxidative stress and inflammation in iron-overloaded Patients with b-thalassemia or sickle cell disease. Br J Haematol 2006;135:254-63.
16. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38:698-710.
17. Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, Ames BN, et al. Biomarkers of oxidative stress study: III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic Biol Med 2005;15:25-40.
18. Tong PC, Ng MC, Ho CS, So WY, Li JK, Lam CW, et al. C-reactive protein and insulin resistance in subjects with thalassemia minor and a family history of diabetes. Diabet Care 2002;25:1480-1.
19. Archararit N, Chuncharunee S, Pornvoranunt A, Atamasirikul K, Rachakom B, Atichartakarn V. Serum C-reactive protein level in postsplenectomized thalassemic patients. J Med Assoc Thai 2000;83[Suppl 1]:S63-9.
20. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003;21:315-25.
21. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2003;23:650-5.
22. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
23. Yeo HC, Helbock HJ, Chyu DW, Ames BN. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem 1994;220:391-6.
24. Yeo HC, Liu J, Helbock HJ, Ames BN. Assay of malondialdehyde and other alkanals in biological fluids by gas chromatography-mass spectrometry. Methods Enzymol 1999;300:70-8.
25. Houglum K, Filip M, Witztum JL, Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest 1990;86:1991-8.
26. Houglum K, Ramm GA, Crawford DH, Witztum JL, Powell LW, Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor b1 in genetic hemochromatosis.Hepatology 1997;26:605-10.
27. Hansen LG, Warwick WJ. An improved assay method for serum vitamins A and E using fluorometry. Am J Clin Pathol 1978;70:922-3.
28. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin-bound iron. Anal Biochem 1990;186:320-3.
29. Evans RW, Williams J. Studies of the binding of different iron donors to human serum transferrin and isolation of iron-binding fragments from the N- and C-terminal regions of the protein. Biochem J 1978;173:543-52.
30. Fischer R. Liver iron susceptometry. In: Andrae W, Nowak H, editors. Magnetism in medicine. A Handbook. Berlin: Wiley-VCH, 1998. p. 286-301.
31. Fung E, Fischer R, Pakbaz Z. The New SQUID biosusceptometer at Oakland: first year of experience. Neurol Clin Neurophysiol 2004;5.
32. Fischer R, Harmatz P, Nielsen P. Does liver biopsy overestimate liver iron concentration? Blood 2006;108:1775-6.
33. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York: John Wiley & Sons, Inc., 2002.
34. Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, Boddupalli S, et al. α and γ tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 2003;64:978-91.
35. Scott MD, van den Berg JJ, Repka T, Rouyer-Fessard P, Hebbel RP, Beuzard Y, et al. Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes. J Clin Invest 1993;91:1706-12.
36. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator. Blood 2004;104:1504-10.
37. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003;101:4148-54.
38. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989;74:844-51.
39. Ludwiczek S, Theurl I, Artner-Dworzak E, Chorney M, Weiss G. Duodenal HFE expression and hepcidin levels determine body iron homeostasis: modulation by genetic diversity and dietary iron availability. J Mol Med 2004;82:373-82.
40. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
41. Pippard MJ. Secondary iron overload. In: Brock JH, Halliday JW, Pippard MJ, eds. Iron metabolism in health and disease. London: W.B. Saunders Ltd.; 1994. p. 272-300.
42. Liu J, Yeo HC, Doniger SJ, Ames BN. Assay of aldehydes from lipid peroxidation: gas chromatography-mass spectrometry compared to thiobarbituric acid. Anal Biochem 1997; 245:161-6.
43. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, et al. Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305-10.
44. Knutson MD, Walter PB, Ames BN, Viteri FE. Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. J Nutr 2000;130:621-8.
45. Walter PB, Knutson MD, Paler-Martinez A, Lee S, Xu Y, Viteri FE, et al. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proc Natl Acad Sci USA 2002;99:2264-9.
46. Laksmitawati DR, Handayani S, Udyaningsih-Freisleben SK, Kurniati V, Adhiyanto C, Hidayat J, et al. Iron status and oxidative stress in β-thalassemia patients in Jakarta. Biofactors 2003;19:53-62.
47. Livrea MA, Tesoriere L, Maggio A, D'Arpa D, Pintaudi AM, Pedone E. Oxidative modification of low-density lipoprotein and atherogenetic risk in β-thalassemia. Blood 1998;92:3936-42.
48. Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, et al. Oxidative stress and antioxidant status in β-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996;88:3608-14.
49. Grosse R, Lund U, Caruso V, Fischer R, Janka GE, Magnano C, et al. Non-transferrin-bound iron during blood transfusion cycles in β-thalassemia major. Ann N Y Acad Sci 2005;1054:429-32.
50. Rachmilewitz EA. The role of intracellular hemoglobin precipitation, low MCHC, and iron overload on red blood cell membrane peroxidation in thalassemia. Birth Defects Orig Artic Ser 1976;12:123-33.
51. Rachmilewitz EA, Shohet SB, Lubin BH. Lipid membrane peroxidation in β-thalassemia major. Blood 1976;47:495-505.
52. Rachmilewitz EA, Weizer-Stern O, Adamsky K, Amariglio N, Rechavi G, Breda L, et al. Role of iron in inducing oxidative stress in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants? Ann NY Acad Sci 2005; 1054:118-23.
53. Tesoriere L, D'Arpa D, Butera D, Allegra M, Renda D, Maggio A, et al. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients. Free Radic Res 2001;34:529-40.
54. Jain SK, Rains JL, Croad JL. High glucose and ketosis (acetoacetate) increases, and chromium niacinate decreases, IL-6, IL-8, and MCP-1 secretion and oxidative stress in U937 monocytes. Antioxid Redox Signal 2007;9:1581-90.
55. Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res 2002;36:1331-6.
56. Fuller GM, Bunzel RJ, Woloski BM, Nham SU. Isolation of hepatocyte stimulating factor from human monocytes. Biochemical and biophysical research communications. 1987;144:1003-9.
57. Bauer J, Ganter U, Geiger T, Jacobshagen U, Hirano T, Matsuda T, et al. Regulation of interleukin-6 expression in cultured human blood monocytes and monocyte-derived macrophages. Blood 1988;72:1134-40.
58. Woloski BM, Fuller GM. Identification and partial characterization of hepatocyte-stimulating factor from leukemia cell lines: comparison with interleukin 1. Proc Natl Acad Sci USA 1985;82:1443-7.
59. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-5.
60. Kushner I, Rzewnicki DL. The acute phase response: general aspects. Bailliere's Clin Rheumatol 1994;8:513-30.
61. Li SP, Goldman ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 1996;35:9060-8.
62. Majello B, Arcone R, Toniatti C, Ciliberto G. Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter. EMBO J 1990;9:457-65.